![]() |
市场调查报告书
商品编码
1289777
全球蛋白质工程市场 - 2023-2030年Global Protein Engineering Market - 2023-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
全球蛋白质工程市场在2022年达到22.472亿美元,预计到2030年将见证有利可图的增长,达到67.213亿美元。在预测期间(2023-2030年),全球蛋白质工程市场预计将呈现15.2%的复合增长率。
蛋白质工程是改变或开发蛋白质的过程,以改善现有特性或增加额外功能。它还需要对蛋白质的结构、序列和特性进行修补,以提高其稳定性、特异性、活性和其他理想的特征。
由于技术的发展,对基于蛋白质的药品需求的增加,以及蛋白质在许多领域的用途的扩大,全球蛋白质工程市场正在迅速发展。
全球蛋白质工程市场的主要驱动力之一是随着糖尿病发病率的上升,对基于蛋白质的治疗药物的需求不断增加。根据CDC的2022年全国糖尿病统计报告,美国有3730万人患有糖尿病,占总人口的11.3%。
由于美国糖尿病发病率的上升,预计对胰岛素以及蛋白工程人工胰岛素的需求将上升。因此,由于上述因素,全球蛋白质工程市场将在预测期内得到提升。
蛋白质工程需要利用先进的工具和设备,如质谱仪、色谱系统和高通量筛选平台。这类设备的购买、维护和改进都很昂贵。
仪器的高成本是投资蛋白质工程技术的一个障碍,特别是对于资源有限的中小型企业(SME)或研究机构。由于这个原因,全球蛋白质工程市场在预测期内将面临一个主要的制约因素。
COVID-19大流行病对蛋白质工程业务产生了实质性的影响,对治疗和诊断的需求增加推动了研究和开发活动。蛋白质工程方法已被用于疫苗开发、抗病毒药物设计和诊断测试开发。
合作、融资以及研究重点转向病毒蛋白和免疫反应,推动了蛋白质工程的进步。然而,供应链的中断也带来了困难。总的来说,这场大流行强调了蛋白质工程在解决全球健康问题方面的重要性,并推动了该领域的创新。
俄罗斯和乌克兰之间的战争对全球蛋白质工程行业的直接影响有限。然而,间接的影响,如供应链中断、经济不稳定、研究合作紧张、人才迁移和监管变化/贸易壁垒都是可能的。
这些因素可能对资源可用性、投资决策、研究资金、科学发展和全球蛋白质工程的人才库产生影响。然而,必须强调的是,地缘政治冲突只是影响该行业的几个变量之一,科学发展和市场需求具有更大的影响。
The Global Protein Engineering Market reached US$ 2,247.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 6,721.3 million by 2030. The global protein engineering market is expected to exhibit a CAGR of 15.2% during the forecast period (2023-2030).
Protein engineering is the process of altering or developing proteins in order to improve existing characteristics or add additional functionality. It also entails tinkering with protein structure, sequence, and characteristics in order to increase their stability, specificity, activity, and other desirable traits.
The global protein engineering market is developing rapidly as a result of technological developments, rising demand for protein-based pharmaceuticals, and the expanding uses of proteins in numerous sectors.
One of the major drivers of the worldwide protein engineering market is the increasing need for protein-based therapeutics as the frequency of diabetes rises. According to the CDC's National Diabetes Statistics Report for 2022, 37.3 million people in the United States have diabetes, accounting for 11.3% of the total population.
Because of the rising prevalence of diabetes in the United States, demand for insulin, as well as protein-engineered artificial insulin, is predicted to rise. Therefore, owing to the above factor the global protein engineering market will boost over the forecast period.
Protein engineering requires the utilization of advanced tools and equipment such as mass spectrometers, chromatography systems, and high-throughput screening platforms. Such equipment can be costly to buy, maintain, and improve.
The high cost of instruments is a barrier to investment in protein engineering technologies, particularly for small and medium-sized firms (SMEs) or research institutes with restricted resources. Owing to this reason the global protein engineering market will face a major restraint over the forecast period.
The COVID-19 pandemic has had a substantial influence on the protein engineering business, with increasing demand for treatments and diagnostics driving research and development activities. Protein engineering approaches have been used in vaccine development, antiviral medication design, and diagnostic test development.
Collaboration, financing, and a shift in research focus to viral proteins and immunological responses have propelled advances in protein engineering. However, supply chain interruptions have presented difficulties. Overall, the pandemic has highlighted the relevance of protein engineering in tackling global health issues and has fueled innovation in the area.
The war between Russia and Ukraine has had a limited direct influence on the global protein engineering industry. However, indirect repercussions such as supply chain disruptions, economic instability, strained research collaborations, talent migration, and regulatory changes/trade barriers are possible.
These factors may have an impact on resource availability, investment decisions, research funding, scientific development, and the global talent pool in protein engineering. However, it is vital to highlight that geopolitical conflicts are only one of several variables influencing the industry, with scientific developments and market demand having a larger impact.
The global protein engineering market is segmented based on product type, protein type, technology, end user, and region.
The biopharmaceutical companies segment is projected to dominate the protein engineering market and will account for the highest market share of 52.5%, due to the high proportion utilization of in silico drug research models for treating diabetes, cancer, and neurological illnesses. For example, top pharmaceutical firms such as Novo Nordisk, AstraZeneca, and Eli Lilly have prioritized revenue growth through the discovery of novel treatments.
Furthermore, the biopharmaceutical companies segment is expanding due to increased financing and investment assistance from both public and private healthcare organizations. For instance, in March 2023, Sanofi's acquisition of Provention Bio brought a new, first-in-class medication for type 1 diabetes to its general medicines core asset portfolio. Therefore, the adoption of in-silico techniques and an increase in funding will drive the segment growth of the global protein engineering market size over the forecast period.
The global protein engineering market is dominated by North America and holds 2/5th market share due to better healthcare spending, technological advancements, presence of major market players leading to drug development, collaboration, and advanced healthcare infrastructure.
For instance, in January 2023. Proteinea, a biotech startup based in the U.S. and Egypt, is pioneering computational protein engineering technology, as they are releasing Ankh, the most sophisticated and high-performing open-source protein language model in the world. Proteinea created Ankh in collaboration with Google and the Technical University of Munich, using funding from Google's cloud innovators program.
The major global players in the market include: GE Healthcare, Thermo Fisher Scientific, Agilent Technologies, Bio-Rad Laboratories, Bruker Corporation, Genscript Biotech Corporation, Codexis, Waters Corporation, New England Biolabs, and Merck KGaA.
The global protein engineering market report would provide approximately 53 tables, 54 figures and 195 pages.
LIST NOT EXHAUSTIVE